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Background

Methods

Epithelial-mesenchymal transition (EMT) is a critical step in cancer
metastasis. During EMT, epithelial cancer cells lose their cell
polarity and adhesion to acquire migratory and invasive properties.
EMT generates cancer stem-like cells (CSCs) that are involved in
chemoresistance and cancer recurrence. Vimentin is a mesenchymal
marker, which is upregulated during EMT, that functionally increases
motility and migratory properties. Vimentin’s regulation is tightly
controlled through phosphorylation by multiple different kinases.
The small molecule compound, FiVe1 increases the phosphorylation
of vimentin most strikingly at serine-56, a site important for cell
division. When the vimentin phosphorylation process is dysregulated
by FiVe1, cells that have undergone EMT become multinucleated
resulting in a loss of stemness and decreased metastasis in vivo.
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4T1 transduction with vimentin wild type and phospho-mimetic (VIM-S56E) doxycycline inducible vectors.
Western blot verification of doxycycline induced expression of HA-vimentin.
Cells were imaged and counted for multinucleation by immunofluorescence with anti-HA primary antibody with goat anti-rabbit488 secondary and Hoechst dye.
CSCs were quantified through mammosphere suspension assay under serum free conditions with and without doxycycline

Results

Figure 3. HA-VIM expression increased in a doxycycline dose dependent manner. Transduced 4T1 cells were treated with
varying concentrations of doxycycline as indicated. HA and actin was detected by western blot.
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Figure 4. 4T1 murine breast cancer cells mimicking vimentin serine-56 phosphorylation resulted in an increase of multinucleation
relative to cells expressing WT vimentin. A) Quantification of multinucleation (n > 3 nuclei per cell) and B) florescent images of
multinucleation for VIM-S56E and VIM-WT. Anti-HA was used to stain HA-VIM and Hoechst was used to stain nuclei.
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Figure 1. FiVe1 induces increased phosphorylation leading to
multinucleation and stemness inhibition A) Western blot analysis
of different vimentin phosphosites. B) Multinucleation images
following FiVe1 treatment. C) Quantified mammosphere formation
following FiVe1. From Bollong et al. PNAS 2017.
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Hypothesis
Mimicking vimentin phosphorylation with a glutamic
substitution at serine-56 will lead to increased multinucleation
and decreased mammosphere formation.
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Figure 5. 4T1 murine breast cancer cells mimicking phosphorylation of vimentin at serine-56 (VIM-S56E) resulted in a decrease
of multinucleation relative to cells expressing WT vimentin (VIM-WT). A) Quantification of mammosphere formation (greater than
80 µm in diameter) and B) images of mammosphere formation for VIM-S56E and VIM-WT under indicated conditions. Scale is 100 µm.
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Figure 2. Depiction of vimentin phosphomimic mutation.

Vimentin phospho-mimetic mutation for serine-56 results in multinucleation and inhibition of stemness in 4T1 cells.
Serine-56 hyperphosphorylation in vimentin is the mechanism behind the ability of FiVe1 to disrupt EMT-enriched carcinoma cells.
The increased phosphorylation of vimentin by FiVe1 at serine-56 leads to a loss of stemness properties.
In future works, we plan to conduct mouse studies for gauging the impact of this mutation on metastasis.
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